Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial

Zarehoseinzade et al., Medical Journal of The Islamic Republic of Iran, doi:10.47176/mjiri.35.30

Zarehoseinzade et al., Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct.., Medical Journal of The Islamic Republic of Iran, doi:10.47176/mjiri.35.30

Apr 2021 Source PDF

Twitter
Facebook

All Studies Meta

RCT 80 hospitalized COVID-19 patients in Iran, 40 treated with finasteride, showing no significant differences other than improved oxygen saturation on the 5th day with treatment. There was significantly more patients with diabetes in the control group. 5mg finasteride for 7 days. IRCT20200505047318N1.

Important missing comments or errors? Let us know.

risk of death, 75.0% lower, RR 0.25, p = 0.36, treatment 1 of 40 (2.5%), control 4 of 40 (10.0%), NNT 13.

risk of ICU admission, no change, RR 1.00, p = 1.00, treatment 1 of 40 (2.5%), control 1 of 40 (2.5%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Zarehoseinzade et al., 30 Apr 2021, Randomized Controlled Trial, Iran, peer-reviewed, 5 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Antiandrogens All

Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial

Elham Zarehoseinzade, Abbas Allami, Mehrnoosh Ahmadi, Behzad Bijani, Navid Mohammadi

Medical Journal of The Islamic Republic of Iran, doi:10.47176/mjiri.35.30

Background finasteride mig COVID-19 infe Methods: W patients aged ≥ patients were r drug therapy an and secondary protocol was IR.QUMS.REC significant. Results: We (p= 0.018). Th patients in the f Conclusion: hospitalized m required to help

staff at the B in the study. Conflict of I The authors d

References

Adamowicz, reductase inhi Med Hypothes

Chen, Xu inducible fact transition in

Goren, J, C Mesinkovska N with Reduced Androgenetic, Dermatol

Goren, Mcc, What An insight into

Guan, None, Ni characteristics

Hoffmann, Erichsen, None, Cell

Li, Huang, -19 pa rate of meta-an

Mehta, Mca, None, C immunosuppre

Mikkonen, None, Endocrinol

Moran, Jones, Sharafi, S, outcome of co and over. Int J 14. Hayes AF, P Quantification

Temgoua Mn Belobo, Et, screening of Middle-Incom, Med J

Wambier, Nau, None, Drug

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit